CoChat
Sign Up
Cited by 97CAR-T cell therapy researchImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

Strategies to enhance CAR-T persistence

Open access
Liu, Yue, An, Lingna, Huang, Ruihao, Xiong, Jingkang, Yang, Haoyu, Wang, Xiaoqi, Zhang, Xi·2022·Biomarker Research
DOI 10.1186/s40364-022-00434-9PMC PMC9685914
Open this paper in CoChat — free accountOpen PDF

Abstract

Chimeric antigen receptor T (CAR-T) cell therapy has significantly improved the life expectancy for patients with refractory or relapse B cell lymphoma. As for B cell acute lymphoblastic leukemia (B-ALL), although the primary response rate is promising, the high incidence of early relapse has caused modest long-term survival with CAR-T cell alone. One of the main challenges is the limited persistence of CAR-T cells. To further optimize the clinical effects of CAR-T cells, many studies have focused on modifying the CAR structure and regulating CAR-T cell differentiation. In this review, we focus on CAR-T cell persistence and summarize the latest progress and strategies adopted during the in vitro culture stage to optimize CAR-T immunotherapy by improving long-term persistence. Such strategies include choosing a suitable cell source, improving culture conditions, combining CAR-T cells with conventional drugs, and applying genetic manipulations, all of which may improve the survival of patients with hematologic malignancies by reducing the probability of recurrence after CAR-T cell infusion and provide clues for solid tumor CAR-T cell therapy development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40364-022-00434-9

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • More mature T cell subtypes generally exert greater effector function in vivo.

    “Additionally, we demonstrated for the first time that circulating CAR-T cells at its peak persistence were mostly TCM and TEM, thus confirming that CAR-T cells differentiated into more mature subtypes, which generally exert greater effector function in vivo.33,34”

    From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [34]

    In “Differentiation of T cells influences CAR-T cell efficiency,” the paper says effector T cells are more cytotoxic than central memory T cells and that effector memory cells rapidly perform effector functions after antigen exposure. It does not establish that more mature subtypes generally have greater effector function in vivo; instead, it states that less differentiated TSCM and TCM cells have better persistence and antitumor activity in vivo than TEM and terminal effector cells. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 193

  1. [1]Gross G Waks T Eshhar Z Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proc Natl Acad Sci U S A 1989 86 24 10024 8 10.1073/pnas.86.24.10024 2513569 PMC298636 · DOI
  2. [2]Kochenderfer JN Yu Z Frasheri D Restifo NP Rosenberg SA Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells Blood 2010 116 19 3875 86 10.1182/blood-2010-01-265041 20631379 PMC2981541 · DOI
  3. [3]Milone MC Fish JD Carpenito C Carroll RG Binder GK Teachey D Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo Mol Ther 2009 17 8 1453 64 10.1038/mt.2009.83 19384291 PMC2805264 · DOI · Paper page
  4. [4]Brentjens RJ Rivière I Park JH Davila ML Wang X Stefanski J Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias Blood 2011 118 18 4817 28 10.1182/blood-2011-04-348540 21849486 PMC3208293 · DOI
  5. [5]Gandhi M Jones K Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients Immunotherapy 2011 3 12 1441 3 10.2217/imt.11.135 22091680 · DOI
  6. [6]Micklethwaite KP Savoldo B Hanley PJ Leen AM Demmler-Harrison GJ Cooper LJN Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation Blood 2010 115 13 2695 703 10.1182/blood-2009-09-242263 20110422 PMC2852368 · DOI
  7. [7]Kalos M Levine BL Porter DL Katz S Grupp SA Bagg A T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia Sci Transl Med 2011 3 95 95ra73 10.1126/scitranslmed.3002842 21832238 PMC3393096 · DOI
  8. [8]Hoyos V Savoldo B Quintarelli C Mahendravada A Zhang M Vera J Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety Leukemia 2010 24 6 1160 70 10.1038/leu.2010.75 20428207 PMC2888148 · DOI
  9. [9]Xu Y Zhang M Ramos CA Durett A Liu E Dakhova O Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15 Blood 2014 123 24 3750 9 10.1182/blood-2014-01-552174 24782509 PMC4055922 · DOI
  10. [10]Liu Y Chen X Han W Zhang Y Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia Drugs Today (Barc) 2017 53 11 597 608 10.1358/dot.2017.53.11.2725754 29451276 · DOI
  11. [11]Chavez JC Bachmeier C Kharfan-Dabaja MA CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products Ther Adv Hematol 2019 10 2040620719841581 10.1177/2040620719841581 31019670 PMC6466472 · DOI
  12. [12]Mullard A FDA approves fourth CAR-T cell therapy Nat Rev Drug Discov 2021 20 3 166 33574586
  13. [13]First CAR-T therapy to target BCMA gets FDA nod Nat Biotechnol 2021 39 5 531 10.1038/s41587-021-00929-0 33981079 · DOI · Paper page
  14. [14]Dai H Wu Z Jia H Tong C Guo Y Ti D Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia J Hematol Oncol 2020 13 1 30 10.1186/s13045-020-00856-8 32245502 PMC7126394 · DOI
  15. [15]Melenhorst JJ Chen GM Wang M Porter DL Chen C Collins MA Decade-long leukaemia remissions with persistence of CD4 CAR T cells Nature 2022 602 7897 503 9 10.1038/s41586-021-04390-6 35110735 PMC9166916 · DOI
  16. [16]Zhang C Wang X Zhang R Liu F Wang Y Yan Z Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant Leukemia 2021 35 6 1563 70 10.1038/s41375-020-01056-6 33077866 PMC8179843 · DOI
  17. [17]O’Leary MC Lu X Huang Y Lin X Mahmood I Przepiorka D FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia Clin Cancer Res 2019 25 4 1142 6 10.1158/1078-0432.CCR-18-2035 30309857 · DOI
  18. [18]Liu J Zhong JF Zhang X Zhang C Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies J Hematol Oncol 2017 10 1 35 10.1186/s13045-017-0405-3 28143567 PMC5282795 · DOI
  19. [19]Roex G Timmers M Wouters K Campillo-Davo D Flumens D Schroyens W Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma J Hematol Oncol 2020 13 1 164 10.1186/s13045-020-01001-1 33272302 PMC7713173 · DOI
  20. [20]Newick K O’Brien S Moon E Albelda SM CAR T Cell Therapy for Solid Tumors Annu Rev Med 2017 68 139 52 10.1146/annurev-med-062315-120245 27860544 · DOI · Paper page
  21. [21]Wagner J Wickman E DeRenzo C Gottschalk S CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? Mol Ther 2020 28 11 2320 39 10.1016/j.ymthe.2020.09.015 32979309 PMC7647674 · DOI
  22. [22]Liu G Rui W Zhao X Lin X Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment Cell Mol Immunol 2021 18 5 1085 95 10.1038/s41423-021-00655-2 33785843 PMC8093220 · DOI
  23. [23]Gao TA Chen YY Engineering Next-Generation CAR-T Cells Overcoming Tumor Hypoxia and Metabolism Annu Rev Chem Biomol Eng 2022 13 193 216 10.1146/annurev-chembioeng-092120-092914 35700528 · DOI
  24. [24]Edeline J Houot R Marabelle A Alcantara M CAR-T cells and BiTEs in solid tumors: challenges and perspectives J Hematol Oncol 2021 14 1 65 10.1186/s13045-021-01067-5 33874996 PMC8054411 · DOI
  25. [25]Levine BL Miskin J Wonnacott K Keir C Global Manufacturing of CAR T Cell Therapy Mol Ther Methods Clin Dev. 2017 4 92 101 10.1016/j.omtm.2016.12.006 28344995 PMC5363291 · DOI · Paper page
  26. [26]Huang R Li X He Y Zhu W Gao L Liu Y Recent advances in CAR-T cell engineering J Hematol Oncol 2020 13 1 86 10.1186/s13045-020-00910-5 32616000 PMC7333410 · DOI
  27. [27]Tong C Zhang Y Liu Y Ji X Zhang W Guo Y Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma Blood 2020 136 14 1632 44 32556247 PMC7596761
  28. [28]Jayaraman J Mellody MP Hou AJ Desai RP Fung AW Pham AHT CAR-T design: Elements and their synergistic function EBioMedicine 2020 58 102931 10.1016/j.ebiom.2020.102931 32739874 PMC7393540 · DOI
  29. [29]Zhao J Lin Q Song Y Liu D Universal CARs, universal T cells, and universal CAR T cells J Hematol Oncol 2018 11 1 132 10.1186/s13045-018-0677-2 30482221 PMC6257951 · DOI
  30. [30]Tokarew N Ogonek J Endres S von Bergwelt-Baildon M Kobold S Teaching an old dog new tricks: next-generation CAR T cells Br J Cancer 2019 120 1 26 37 10.1038/s41416-018-0325-1 30413825 PMC6325111 · DOI
  31. [31]Mazinani M Rahbarizadeh F CAR-T cell potency: from structural elements to vector backbone components Biomark Res 2022 10 1 70 10.1186/s40364-022-00417-w 36123710 PMC9487061 · DOI
  32. [32]Cappell KM Kochenderfer JN A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains Nat Rev Clin Oncol 2021 18 11 715 27 10.1038/s41571-021-00530-z 34230645 · DOI
  33. [33]Kagoya Y Tanaka S Guo T Anczurowski M Wang C-H Saso K A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects Nat Med 2018 24 3 352 9 10.1038/nm.4478 29400710 PMC5839992 · DOI
  34. [34]Textor A Grunewald L Anders K Klaus A Schwiebert S Winkler A CD28 Co-Stimulus Achieves Superior CAR T Cell Effector Function against Solid Tumors Than 4–1BB Co-Stimulus Cancers (Basel). 2021 13 5 1050 10.3390/cancers13051050 33801448 PMC7958604 · DOI
  35. [35]Vinanica N Yong A Wong D Png YT Seow SV Imamura M Specific stimulation of T lymphocytes with erythropoietin for adoptive immunotherapy Blood 2020 135 9 668 79 10.1182/blood.2019001645 31697835 · DOI
  36. [36]Muliaditan T Halim L Whilding LM Draper B Achkova DY Kausar F Synergistic T cell signaling by 41BB and CD28 is optimally achieved by membrane proximal positioning within parallel chimeric antigen receptors Cell Rep Med 2021 2 12 100457 10.1016/j.xcrm.2021.100457 35028604 PMC8714859 · DOI
  37. [37]Wang Y Tong C Dai H Wu Z Han X Guo Y Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming Nat Commun 2021 12 1 409 10.1038/s41467-020-20696-x 33462245 PMC7814040 · DOI
  38. [38]Wang X Rivière I Clinical manufacturing of CAR T cells: foundation of a promising therapy Mol Ther Oncolytics 2016 3 16015 10.1038/mto.2016.15 27347557 PMC4909095 · DOI · Paper page
  39. [39]Hu Y Wang J Wei G Yu J Luo Y Shi J A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic leukemia Bone Marrow Transplant 2019 54 8 1208 17 10.1038/s41409-018-0403-2 30518980 · DOI
  40. [40]Depil S Duchateau P Grupp SA Mufti G Poirot L ’Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat Rev Drug Discov 2020 19 3 185 99 10.1038/s41573-019-0051-2 31900462 · DOI
  41. [41]Qasim W Zhan H Samarasinghe S Adams S Amrolia P Stafford S Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells Sci Transl Med. 2017 9 374 eaaj2013 10.1126/scitranslmed.aaj2013 28123068 · DOI · Paper page
  42. [42]Bartoló-Ibars A Uribe-Herranz M Muñoz-Sánchez G Arnaldos-Pérez C Ortiz-Maldonado V Urbano-Ispizua Á CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies? Cancers (Basel). 2021 13 18 4664 10.3390/cancers13184664 34572890 PMC8470158 · DOI
  43. [43]Hu Y Zhou Y Zhang M Ge W Li Y Yang L CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Clin Cancer Res 2021 27 10 2764 72 10.1158/1078-0432.CCR-20-3863 33627493 · DOI
  44. [44]DiNofia AM Grupp SA Will allogeneic CAR T cells for CD19 malignancies take autologous CAR T cells ‘off the shelf’? Nat Rev Clin Oncol 2021 18 4 195 6 10.1038/s41571-021-00485-1 33608691 · DOI
  45. [45]Chong EA Ruella M Schuster SJ Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy N Engl J Med 2021 384 7 673 4 10.1056/NEJMc2030164 33596362 · DOI
  46. [46]Schuster SJ Svoboda J Chong EA Nasta SD Mato AR Anak Ö Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas N Engl J Med 2017 377 26 2545 54 10.1056/NEJMoa1708566 29226764 PMC5788566 · DOI
  47. [47]Benjamin R Graham C Yallop D Jozwik A Mirci-Danicar OC Lucchini G Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies Lancet 2020 396 10266 1885 94 10.1016/S0140-6736(20)32334-5 33308471 PMC11773457 · DOI
  48. [48]Lin H Cheng J Mu W Zhou J Zhu L Advances in Universal CAR-T Cell Therapy Front Immunol 2021 12 744823 10.3389/fimmu.2021.744823 34691052 PMC8526896 · DOI
  49. [49]van der Stegen SJC Lindenbergh PL Petrovic RM Xie H Diop MP Alexeeva V Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells Nat Biomed Eng. 2022 6 11 1284 1297 10.1038/s41551-022-00915-0 35941192 PMC9669107 · DOI
  50. [50]Adusumilli PS Cherkassky L Villena-Vargas J Colovos C Servais E Plotkin J Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity Sci Transl Med 2014 6 261 261ra151 10.1126/scitranslmed.3010162 25378643 PMC4373413 · DOI
  51. [51]Sommermeyer D Hudecek M Kosasih PL Gogishvili T Maloney DG Turtle CJ Chimeric antigen receptor-modified T cells derived from defined CD8 + and CD4 + subsets confer superior antitumor reactivity in vivo Leukemia 2016 30 2 492 500 10.1038/leu.2015.247 26369987 PMC4746098 · DOI
  52. [55]Franks SE Wolfson B Hodge JW Natural Born Killers: NK Cells in Cancer Therapy Cancers (Basel). 2020 12 8 2131 10.3390/cancers12082131 32751977 PMC7465121 · DOI
  53. [56]Baghery Saghchy Khorasani A Yousefi A-M Bashash D CAR NK cell therapy in hematologic malignancies and solid tumors; obstacles and strategies to overcome the challenges Int Immunopharmacol 2022 110 109041 10.1016/j.intimp.2022.109041 35839565 · DOI
  54. [57]Liu S Galat V Galat Y Lee YKA Wainwright D Wu J NK cell-based cancer immunotherapy: from basic biology to clinical development J Hematol Oncol 2021 14 1 7 10.1186/s13045-020-01014-w 33407739 PMC7788999 · DOI · Paper page
  55. [58]Yilmaz A Cui H Caligiuri MA Yu J Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy J Hematol Oncol 2020 13 1 168 10.1186/s13045-020-00998-9 33287875 PMC7720606 · DOI · Paper page
  56. [60]Zhang L Meng Y Feng X Han Z CAR-NK cells for cancer immunotherapy: from bench to bedside Biomark Res 2022 10 1 12 10.1186/s40364-022-00364-6 35303962 PMC8932134 · DOI
  57. [61]Delfanti G Dellabona P Casorati G Fedeli M Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment Front Med (Lausanne) 2022 9 897750 10.3389/fmed.2022.897750 35615083 PMC9125179 · DOI
  58. [62]Heczey A Liu D Tian G Courtney AN Wei J Marinova E Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy Blood 2014 124 18 2824 33 10.1182/blood-2013-11-541235 25049283 PMC4215313 · DOI
  59. [63]Heczey A Courtney AN Montalbano A Robinson S Liu K Li M Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis Nat Med 2020 26 11 1686 90 10.1038/s41591-020-1074-2 33046868 · DOI
  60. [64]Xu X Huang W Heczey A Liu D Guo L Wood M NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Persistence and Antitumor Activity against Neuroblastoma Clin Cancer Res 2019 25 23 7126 38 10.1158/1078-0432.CCR-19-0421 31484667 PMC6891170 · DOI
  61. [65]Silva-Santos B Mensurado S Coffelt SB γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer Nat Rev Cancer 2019 19 7 392 404 10.1038/s41568-019-0153-5 31209264 PMC7614706 · DOI
  62. [66]Silva-Santos B Serre K Norell H γδ T cells in cancer Nat Rev Immunol 2015 15 11 683 91 10.1038/nri3904 26449179 · DOI · Paper page
  63. [67]Legut M Cole DK Sewell AK The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy Cell Mol Immunol 2015 12 6 656 68 10.1038/cmi.2015.28 25864915 PMC4716630 · DOI
  64. [68]Ou L Wang H Huang H Zhou Z Lin Q Guo Y Preclinical platforms to study therapeutic efficacy of human γδ T cells Clin Transl Med 2022 12 6 e814 10.1002/ctm2.814 35731974 PMC9217106 · DOI
  65. [69]Lee D Rosenthal CJ Penn NE Dunn ZS Zhou Y Yang L Human γδ T Cell Subsets and Their Clinical Applications for Cancer Immunotherapy Cancers (Basel). 2022 14 12 3005 10.3390/cancers14123005 35740670 PMC9221220 · DOI
  66. [70]Rozenbaum M Meir A Aharony Y Itzhaki O Schachter J Bank I Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia Front Immunol 2020 11 1347 10.3389/fimmu.2020.01347 32714329 PMC7343910 · DOI
  67. [71]Nishimoto KP Barca T Azameera A Makkouk A Romero JM Bai L Allogeneic CD20-targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B-cell lymphoma models Clin Transl Immunology 2022 11 2 e1373 10.1002/cti2.1373 35136603 PMC8809437 · DOI
  68. [72]Jin K Parreau S Warrington KJ Koster MJ Berry GJ Goronzy JJ Regulatory T Cells in Autoimmune Vasculitis Front Immunol 2022 13 844300 10.3389/fimmu.2022.844300 35296082 PMC8918523 · DOI
  69. [73]Richardson N Wootton GE Bozward AG Oo YH Challenges and opportunities in achieving effective regulatory T cell therapy in autoimmune liver disease Semin Immunopathol 2022 44 4 461 74 10.1007/s00281-022-00940-w 35641679 PMC9256571 · DOI
  70. [74]Arjomandnejad M Kopec AL Keeler AM CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications Biomedicines. 2022 10 2 287 10.3390/biomedicines10020287 35203496 PMC8869296 · DOI
  71. [75]Ellis GI Coker KE Winn DW Deng MZ Shukla D Bhoj V Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque Cell Rep Med 2022 3 5 100614 10.1016/j.xcrm.2022.100614 35551746 PMC9133392 · DOI
  72. [76]Qu G Chen J Li Y Yuan Y Liang R Li B Current status and perspectives of regulatory T cell-based therapy J Genet Genomics 2022 49 7 599 611 10.1016/j.jgg.2022.05.005 35636740 · DOI
  73. [77]van den Broek T Borghans JAM van Wijk F The full spectrum of human naive T cells Nat Rev Immunol 2018 18 6 363 73 10.1038/s41577-018-0001-y 29520044 · DOI
  74. [78]Golubovskaya V Wu L Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy Cancers (Basel). 2016 8 3 36 10.3390/cancers8030036 26999211 PMC4810120 · DOI
  75. [79]Tantalo DG Oliver AJ von Scheidt B Harrison AJ Mueller SN Kershaw MH Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies J Immunother Cancer. 2021 9 5 e002555 10.1136/jitc-2021-002555 34035114 PMC8154965 · DOI
  76. [81]Lugli E Dominguez MH Gattinoni L Chattopadhyay PK Bolton DL Song K Superior T memory stem cell persistence supports long-lived T cell memory J Clin Investig 2013 123 2 594 9 23281401 PMC3561805
  77. [82]Ando M Ito M Srirat T Kondo T Yoshimura A Memory T cell, exhaustion, and tumor immunity Immunol Med 2020 43 1 1 9 10.1080/25785826.2019.1698261 31822213 · DOI
  78. [83]Lugli E Galletti G Boi SK Youngblood BA Stem, Effector, and Hybrid States of Memory CD8 T Cells Trends Immunol 2020 41 1 17 28 10.1016/j.it.2019.11.004 31810790 PMC6934921 · DOI
  79. [84]Klebanoff CA Gattinoni L Restifo NP Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy? J Immunother 2012 35 9 651 60 10.1097/CJI.0b013e31827806e6 23090074 PMC3501135 · DOI
  80. [85]Klebanoff CA Gattinoni L Torabi-Parizi P Kerstann K Cardones AR Finkelstein SE Central memory self/tumor-reactive CD8 + T cells confer superior antitumor immunity compared with effector memory T cells Proc Natl Acad Sci U S A 2005 102 27 9571 6 10.1073/pnas.0503726102 15980149 PMC1172264 · DOI
  81. [86]Wang X Popplewell LL Wagner JR Naranjo A Blanchard MS Mott MR Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL Blood 2016 127 24 2980 90 10.1182/blood-2015-12-686725 27118452 PMC4911862 · DOI
  82. [87]López-Cantillo G Urueña C Camacho BA Ramírez-Segura C CAR-T Cell Performance: How to Improve Their Persistence? Front Immunol 2022 13 878209 10.3389/fimmu.2022.878209 35572525 PMC9097681 · DOI · Paper page
  83. [88]Gattinoni L Klebanoff CA Restifo NP Paths to stemness: building the ultimate antitumour T cell Nat Rev Cancer 2012 12 10 671 84 10.1038/nrc3322 22996603 PMC6352980 · DOI
  84. [89]Brummelman J Pilipow K Lugli E The Single-Cell Phenotypic Identity of Human CD8 and CD4 T Cells Int Rev Cell Mol Biol. 2018 341 63 124 10.1016/bs.ircmb.2018.05.007 30262035 · DOI
  85. [90]Sabatino M Hu J Sommariva M Gautam S Fellowes V Hocker JD Generation of clinical-grade CD19-specific CAR-modified CD8 + memory stem cells for the treatment of human B-cell malignancies Blood 2016 128 4 519 28 10.1182/blood-2015-11-683847 27226436 PMC4965906 · DOI
  86. [91]Arcangeli S Falcone L Camisa B De Girardi F Biondi M Giglio F Next-Generation Manufacturing Protocols Enriching T CAR T Cells Can Overcome Disease-Specific T Cell Defects in Cancer Patients Front Immunol 2020 11 1217 10.3389/fimmu.2020.01217 32636841 PMC7317024 · DOI · Paper page
  87. [92]Zhang Z Li F Tian Y Cao L Gao Q Zhang C Metformin Enhances the Antitumor Activity of CD8 T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway J Immunol 2020 204 9 2575 88 10.4049/jimmunol.1901213 32221038 · DOI
  88. [93]Zhang M Jin X Sun R Xiong X Wang J Xie D Optimization of metabolism to improve efficacy during CAR-T cell manufacturing J Transl Med 2021 19 1 499 10.1186/s12967-021-03165-x 34876185 PMC8650271 · DOI
  89. [94]Kouidhi S Elgaaied AB Chouaib S Impact of Metabolism on T-Cell Differentiation and Function and Cross Talk with Tumor Microenvironment Front Immunol 2017 8 270 10.3389/fimmu.2017.00270 28348562 PMC5346542 · DOI
  90. [95]Patel CH Powell JD Warburg meets epigenetics Science (New York, NY). 2016 354 6311 419 20 10.1126/science.aak9776 27789830 · DOI
  91. [96]Bishop EL Gudgeon N Dimeloe S Control of T Cell Metabolism by Cytokines and Hormones Front Immunol 2021 12 653605 10.3389/fimmu.2021.653605 33927722 PMC8076900 · DOI
  92. [97]Loschinski R Böttcher M Stoll A Bruns H Mackensen A Mougiakakos D IL-21 modulates memory and exhaustion phenotype of T-cells in a fatty acid oxidation-dependent manner Oncotarget 2018 9 17 13125 38 10.18632/oncotarget.24442 29568345 PMC5862566 · DOI
  93. [98]Huang Y Si X Shao M Teng X Xiao G Huang H Rewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells J Hematol Oncol 2022 15 1 38 10.1186/s13045-022-01255-x 35346311 PMC8960222 · DOI
  94. [99]Gong W Hoffmann J-M Stock S Wang L Liu Y Schubert M-L Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells Cancer Immunol Immunother 2019 68 7 1195 209 10.1007/s00262-019-02354-4 31177329 PMC11028180 · DOI
  95. [100]Alizadeh D Wong RA Yang X Wang D Pecoraro JR Kuo C-F IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Cancer Immunol Res 2019 7 5 759 72 10.1158/2326-6066.CIR-18-0466 30890531 PMC6687561 · DOI
  96. [101]Sukumar M Liu J Ji Y Subramanian M Crompton JG Yu Z Inhibiting glycolytic metabolism enhances CD8 + T cell memory and antitumor function J Clin Invest 2013 123 10 4479 88 10.1172/JCI69589 24091329 PMC3784544 · DOI · Paper page
  97. [102]Marchesi F Vignali D Manini B Rigamonti A Monti P Manipulation of Glucose Availability to Boost Cancer Immunotherapies Cancers (Basel). 2020 12 10 2940 10.3390/cancers12102940 33053779 PMC7650629 · DOI
  98. [103]Geiger R Rieckmann JC Wolf T Basso C Feng Y Fuhrer T L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity Cell. 2016 167 3 829 842.e13 10.1016/j.cell.2016.09.031 27745970 PMC5075284 · DOI · Paper page
  99. [104]Nabe S Yamada T Suzuki J Toriyama K Yasuoka T Kuwahara M Reinforce the antitumor activity of CD8 T cells via glutamine restriction Cancer Sci 2018 109 12 3737 50 10.1111/cas.13827 30302856 PMC6272119 · DOI
  100. [106]Shen L Xiao Y Zhang C Li S Teng X Cui L Metabolic reprogramming by ex vivo glutamine inhibition endows CAR-T cells with less-differentiated phenotype and persistent antitumor activity Cancer Lett 2022 538 215710 10.1016/j.canlet.2022.215710 35489446 · DOI
  101. [107]Ghassemi S Martinez-Becerra FJ Master AM Richman SA Heo D Leferovich J Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design Mol Ther Methods Clin Dev 2020 18 595 606 10.1016/j.omtm.2020.07.008 32775494 PMC7397397 · DOI
  102. [108]Schöffski P Cresta S Mayer IA Wildiers H Damian S Gendreau S A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer Breast Cancer Res 2018 20 1 109 10.1186/s13058-018-1015-x 30185228 PMC6125885 · DOI
  103. [109]Stock S Übelhart R Schubert M-L Fan F He B Hoffmann J-M Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients Int J Cancer 2019 145 5 1312 24 10.1002/ijc.32201 30737788 · DOI
  104. [110]Funk CR Wang S Chen KZ Waller A Sharma A Edgar CL PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity Blood 2022 139 4 523 37 10.1182/blood.2021011597 35084470 PMC8796652 · DOI
  105. [111]Fan F Yoo HJ Stock S Wang L Liu Y Schubert M-L Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients Int J Cancer 2021 148 2 419 28 10.1002/ijc.33212 32683672 · DOI
  106. [112]Zheng W O’Hear CE Alli R Basham JH Abdelsamed HA Palmer LE PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells Leukemia 2018 32 5 1157 67 10.1038/s41375-017-0008-6 29479065 PMC5943191 · DOI
  107. [113]Nian Z Zheng X Dou Y Du X Zhou L Fu B Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells Clin Cancer Res 2021 27 21 6026 38 10.1158/1078-0432.CCR-21-0452 34233960 PMC9401534 · DOI
  108. [114]Lei X Ou Z Yang Z Zhong J Zhu Y Tian J A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors Clin Cancer Res 2021 27 13 3757 71 10.1158/1078-0432.CCR-20-2487 33811153 PMC8722110 · DOI
  109. [115]Kong W Dimitri A Wang W Jung I-Y Ott CJ Fasolino M BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia J Clin Invest. 2021 131 16 e145459 10.1172/JCI145459 34396987 PMC8363276 · DOI
  110. [116]Shen C Zhang Z Tian Y Li F Zhou L Jiang W Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway BMC Med 2021 19 1 283 10.1186/s12916-021-02161-8 34819055 PMC8614004 · DOI
  111. [118]Yang Q Jiang W Hou P Emerging role of PI3K/AKT in tumor-related epigenetic regulation Semin Cancer Biol 2019 59 112 24 10.1016/j.semcancer.2019.04.001 30951826 · DOI
  112. [119]Wang X Ding J Meng L-h PI3K isoform-selective inhibitors: next-generation targeted cancer therapies Acta Pharmacol Sin 2015 36 10 1170 6 10.1038/aps.2015.71 26364801 PMC4648175 · DOI
  113. [120]Bertacchini J Heidari N Mediani L Capitani S Shahjahani M Ahmadzadeh A Targeting PI3K/AKT/mTOR network for treatment of leukemia Cell Mol Life Sci 2015 72 12 2337 47 10.1007/s00018-015-1867-5 25712020 PMC11113278 · DOI
  114. [121]Saravia J Raynor JL Chapman NM Lim SA Chi H Signaling networks in immunometabolism Cell Res 2020 30 4 328 42 10.1038/s41422-020-0301-1 32203134 PMC7118125 · DOI
  115. [122]Hasslacher S Schneele L Stroh S Langhans J Zeiler K Kattner P Inhibition of PI3K signalling increases the efficiency of radiotherapy in glioblastoma cells Int J Oncol 2018 53 5 1881 96 30132519 PMC6192725
  116. [123]Zhang H Hu Y Shao M Teng X Jiang P Wang X Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion J Hematol Oncol 2021 14 1 113 10.1186/s13045-021-01117-y 34289897 PMC8293573 · DOI
  117. [124]Alu A Lei H Han X Wei Y Wei X BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies J Hematol Oncol 2022 15 1 138 10.1186/s13045-022-01353-w 36183125 PMC9526392 · DOI
  118. [125]Wang H Guo H Yang J Liu Y Liu X Zhang Q Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect Exp Hematol Oncol 2022 11 1 60 10.1186/s40164-022-00315-9 36138486 PMC9493169 · DOI
  119. [126]Ghez D Rubio MT Maillard N Suarez F Chandesris M-O Delarue R Rapamycin for refractory acute graft-versus-host disease Transplantation 2009 88 9 1081 7 10.1097/TP.0b013e3181ba0a13 19898203 · DOI
  120. [127]Akbari B Ghahri-Saremi N Soltantoyeh T Hadjati J Ghassemi S Mirzaei HR Epigenetic strategies to boost CAR T cell therapy Mol Ther 2021 29 9 2640 59 10.1016/j.ymthe.2021.08.003 34365035 PMC8417511 · DOI
  121. [128]Belk JA Daniel B Satpathy AT Epigenetic regulation of T cell exhaustion Nat Immunol 2022 23 6 848 60 10.1038/s41590-022-01224-z 35624210 PMC10439681 · DOI
  122. [129]Sen DR Kaminski J Barnitz RA Kurachi M Gerdemann U Yates KB The epigenetic landscape of T cell exhaustion 2016 New York Science 1165 9 PMC5497589 27789799
  123. [130]Akimova T Beier UH Liu Y Wang L Hancock WW Histone/protein deacetylases and T-cell immune responses Blood 2012 119 11 2443 51 10.1182/blood-2011-10-292003 22246031 PMC3311271 · DOI
  124. [132]Li Y Seto E HDACs and HDAC Inhibitors in Cancer Development and Therapy Cold Spring Harb Perspect Med. 2016 6 10 a026831 10.1101/cshperspect.a026831 27599530 PMC5046688 · DOI
  125. [133]Que Y Zhang X-L Liu Z-X Zhao J-J Pan Q-Z Wen X-Z Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma J Immunother Cancer. 2021 9 2 e001696 10.1136/jitc-2020-001696 33637599 PMC7919591 · DOI
  126. [134]Sanchez-Rangel E Inzucchi SE Metformin: clinical use in type 2 diabetes Diabetologia 2017 60 9 1586 93 10.1007/s00125-017-4336-x 28770321 · DOI
  127. [135]Cioce M Pulito C Strano S Blandino G Fazio VM Metformin: Metabolic Rewiring Faces Tumor Heterogeneity Cells. 2020 9 11 2439 10.3390/cells9112439 33182253 PMC7695274 · DOI
  128. [136]Ma T Tian X Zhang B Li M Wang Y Yang C Low-dose metformin targets the lysosomal AMPK pathway through PEN2 Nature 2022 603 7899 159 65 10.1038/s41586-022-04431-8 35197629 PMC8891018 · DOI · Paper page
  129. [137]Singh K Connors SL Macklin EA Smith KD Fahey JW Talalay P Sulforaphane treatment of autism spectrum disorder (ASD) Proc Natl Acad Sci U S A 2014 111 43 15550 5 10.1073/pnas.1416940111 25313065 PMC4217462 · DOI · Paper page
  130. [138]Liu Y Lu Y Xu Z Ma X Chen X Liu W Repurposing of the gold drug auranofin and a review of its derivatives as antibacterial therapeutics Drug Discov Today 2022 27 7 1961 73 10.1016/j.drudis.2022.02.010 35192926 · DOI
  131. [139]Dufva O Koski J Maliniemi P Ianevski A Klievink J Leitner J Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity Blood 2020 135 9 597 609 10.1182/blood.2019002121 31830245 PMC7098811 · DOI · Paper page
  132. [140]Doudna JA Charpentier E Genome editing. The new frontier of genome engineering with CRISPR-Cas9 Science 2014 346 6213 1258096 10.1126/science.1258096 25430774 · DOI · Paper page
  133. [142]Sharma G Sharma AR Bhattacharya M Lee S-S Chakraborty C CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases Mol Ther 2021 29 2 571 86 10.1016/j.ymthe.2020.09.028 33238136 PMC7854284 · DOI
  134. [144]Tang TCY Xu N Nordon R Haber M Micklethwaite K Dolnikov A Donor T cells for CAR T cell therapy Biomark Res 2022 10 1 14 10.1186/s40364-022-00359-3 35365224 PMC8973942 · DOI
  135. [145]Liu X Zhang Y Cheng C Cheng AW Zhang X Li N CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells Cell Res 2017 27 1 154 7 10.1038/cr.2016.142 27910851 PMC5223227 · DOI
  136. [146]Guo Y Tong C Su L Zhang W Jia H Liu Y CRISPR/Cas9 genome-edited universal CAR T cells in patients with relapsed/refractory lymphoma Blood Adv 2022 6 8 2695 9 10.1182/bloodadvances.2021006232 35008103 PMC9043938 · DOI
  137. [147]Dimitri A Herbst F Fraietta JA Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing Mol Cancer 2022 21 1 78 10.1186/s12943-022-01559-z 35303871 PMC8932053 · DOI
  138. [148]Stenger D Stief TA Kaeuferle T Willier S Rataj F Schober K Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR Blood 2020 136 12 1407 18 10.1182/blood.2020005185 32483603 PMC7612202 · DOI
  139. [149]Zhang Y Zhang X Cheng C Mu W Liu X Li N CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells Front Med 2017 11 4 554 62 10.1007/s11684-017-0543-6 28625015 · DOI
  140. [150]Ren J Zhang X Liu X Fang C Jiang S June CH A versatile system for rapid multiplex genome-edited CAR T cell generation Oncotarget 2017 8 10 17002 11 10.18632/oncotarget.15218 28199983 PMC5370017 · DOI
  141. [151]Tian Y Li Y Shao Y Zhang Y Gene modification strategies for next-generation CAR T cells against solid cancers J Hematol Oncol 2020 13 1 54 10.1186/s13045-020-00890-6 32423475 PMC7236186 · DOI
  142. [154]Wiede F Lu K-H Du X Zeissig MN Xu R Goh PK PTP1B Is an Intracellular Checkpoint that Limits T-cell and CAR T-cell Antitumor Immunity Cancer Discov 2022 12 3 752 73 10.1158/2159-8290.CD-21-0694 34794959 PMC8904293 · DOI
  143. [155]Kumar J Kumar R Kumar Singh A Tsakem EL Kathania M Riese MJ Deletion of Cbl-b inhibits CD8 T-cell exhaustion and promotes CAR T-cell function J Immunother Cancer. 2021 9 1 e001688 10.1136/jitc-2020-001688 33462140 PMC7813298 · DOI
  144. [156]Tang N Cheng C Zhang X Qiao M Li N Mu W TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors JCI Insight. 2020 5 4 e133977 10.1172/jci.insight.133977 31999649 PMC7101140 · DOI
  145. [157]Li K, Xu J, Wang J, Lu C, Dai Y, Dai Q, et al. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer. Cancer Immunol Immunother. 2022. PMID: 36166071. 10.1007/s00262-022-03290-6. PMC10025183 36166071 · DOI
  146. [158]Li N Tang N Cheng C Hu T Wei X Han W Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway Oncoimmunology 2020 9 1 1824643 10.1080/2162402X.2020.1824643 33457103 PMC7781731 · DOI
  147. [159]Liu G Zhang Q Liu G Li D Zhang L Gu Z Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo Exp Cell Res 2021 409 1 112886 10.1016/j.yexcr.2021.112886 34673000 · DOI
  148. [160]Adachi K Kano Y Nagai T Okuyama N Sakoda Y Tamada K IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor Nat Biotechnol 2018 36 4 346 51 10.1038/nbt.4086 29505028 · DOI
  149. [161]Zhang Z Miao L Ren Z Tang F Li Y Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future Front Immunol 2021 12 718686 10.3389/fimmu.2021.718686 34386015 PMC8353254 · DOI
  150. [162]Kueberuwa G Kalaitsidou M Cheadle E Hawkins RE Gilham DE CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity Mol Ther Oncolytics 2018 8 41 51 10.1016/j.omto.2017.12.003 29367945 PMC5772011 · DOI
  151. [163]Avanzi MP Yeku O Li X Wijewarnasuriya DP van Leeuwen DG Cheung K Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System Cell Rep 2018 23 7 2130 41 10.1016/j.celrep.2018.04.051 29768210 PMC5986286 · DOI
  152. [164]Štach M Ptáčková P Mucha M Musil J Klener P Otáhal P Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells Cytotherapy 2020 22 12 744 54 10.1016/j.jcyt.2020.08.005 32950390 · DOI
  153. [165]Ma X Shou P Smith C Chen Y Du H Sun C Interleukin-23 engineering improves CAR T cell function in solid tumors Nat Biotechnol 2020 38 4 448 59 10.1038/s41587-019-0398-2 32015548 PMC7466194 · DOI
  154. [166]Foeng J Comerford I McColl SR Harnessing the chemokine system to home CAR-T cells into solid tumors Cell Rep Med 2022 3 3 100543 10.1016/j.xcrm.2022.100543 35492880 PMC9040186 · DOI
  155. [167]Jin L Tao H Karachi A Long Y Hou AY Na M CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors Nat Commun 2019 10 1 4016 10.1038/s41467-019-11869-4 31488817 PMC6728370 · DOI
  156. [168]Moon EK Carpenito C Sun J Wang L-CS Kapoor V Predina J Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor Clin Cancer Res 2011 17 14 4719 30 10.1158/1078-0432.CCR-11-0351 21610146 PMC3612507 · DOI
  157. [169]Wang Y Wang J Yang X Yang J Lu P Zhao L Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model Front Immunol 2021 12 628906 10.3389/fimmu.2021.628906 33777013 PMC7992009 · DOI
  158. [170]Lesch S Blumenberg V Stoiber S Gottschlich A Ogonek J Cadilha BL T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours Nat Biomed Eng 2021 5 11 1246 60 10.1038/s41551-021-00737-6 34083764 PMC7611996 · DOI
  159. [171]Itoh-Nakadai A Saito Y Murasawa-Tomizawa M Kajita H Ishikawa F CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively Eliminate Human AML Cells In Vivo Blood 2020 136 Supplement 1 35 6 10.1182/blood-2020-142228 · DOI
  160. [172]Di Stasi A De Angelis B Rooney CM Zhang L Mahendravada A Foster AE T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model Blood 2009 113 25 6392 402 10.1182/blood-2009-03-209650 19377047 PMC2710932 · DOI · Paper page
  161. [173]Curran KJ Seinstra BA Nikhamin Y Yeh R Usachenko Y van Leeuwen DG Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression Mol Ther 2015 23 4 769 78 10.1038/mt.2015.4 25582824 PMC4395796 · DOI
  162. [174]Zhao Z Condomines M van der Stegen SJC Perna F Kloss CC Gunset G Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells Cancer Cell 2015 28 4 415 28 10.1016/j.ccell.2015.09.004 26461090 PMC5003056 · DOI · Paper page
  163. [175]Kuhn NF Purdon TJ van Leeuwen DG Lopez AV Curran KJ Daniyan AF CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response Cancer Cell. 2019 35 3 473 488.e6 10.1016/j.ccell.2019.02.006 30889381 PMC6428219 · DOI
  164. [176]Tan J Jia Y Zhou M Fu C Tuhin IJ Ye J Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells J Hematol Oncol 2022 15 1 39 10.1186/s13045-022-01244-0 35365211 PMC8974082 · DOI
  165. [177]Li H Tong J Zhu S Batista PJ Duffy EE Zhao J m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways Nature 2017 548 7667 338 42 10.1038/nature23450 28792938 PMC5729908 · DOI
  166. [178]Onishi M Nosaka T Misawa K Mui AL Gorman D McMahon M Identification and characterization of a constitutively active STAT5 mutant that promotes cell proliferation Mol Cell Biol 1998 18 7 3871 9 10.1128/MCB.18.7.3871 9632771 PMC108971 · DOI
  167. [179]Ding Z-C Shi H Aboelella NS Fesenkova K Park E-J Liu Z Persistent STAT5 activation reprograms the epigenetic landscape in CD4 T cells to drive polyfunctionality and antitumor immunity Sci Immunol. 2020 5 52 eaba5962 10.1126/sciimmunol.aba5962 33127608 PMC8265158 · DOI
  168. [180]Macián F García-Cózar F Im S-H Horton HF Byrne MC Rao A Transcriptional mechanisms underlying lymphocyte tolerance Cell 2002 109 6 719 31 10.1016/S0092-8674(02)00767-5 12086671 · DOI
  169. [181]Seo H González-Avalos E Zhang W Ramchandani P Yang C Lio C-WJ BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells Nat Immunol 2021 22 8 983 95 10.1038/s41590-021-00964-8 34282330 PMC8319109 · DOI
  170. [183]Lai P Chen X Wang Y Wang J Zhang Y Geng S C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction J Hematol Oncol 2022 15 1 68 10.1186/s13045-022-01288-2 35597971 PMC9124432 · DOI
  171. [184]Weng J Lai P Qin L Lai Y Jiang Z Luo C A novel generation 1928zT2 CAR T cells induce remission in extramedullary relapse of acute lymphoblastic leukemia J Hematol Oncol 2018 11 1 25 10.1186/s13045-018-0572-x 29458388 PMC5819207 · DOI
  172. [185]Lai Y Weng J Wei X Qin L Lai P Zhao R Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells Leukemia 2018 32 3 801 8 10.1038/leu.2017.249 28841215 · DOI
  173. [186]Chow RD Chen S Cancer CRISPR Screens In Vivo Trends Cancer 2018 4 5 349 58 10.1016/j.trecan.2018.03.002 29709259 PMC5935117 · DOI
  174. [187]Liu D Zhao X Tang A Xu X Liu S Zha L CRISPR screen in mechanism and target discovery for cancer immunotherapy Biochim Biophys Acta Rev Cancer 2020 1874 1 188378 10.1016/j.bbcan.2020.188378 32413572 · DOI
  175. [188]Shang W Jiang Y Boettcher M Ding K Mollenauer M Liu Z Genome-wide CRISPR screen identifies FAM49B as a key regulator of actin dynamics and T cell activation Proc Natl Acad Sci U S A 2018 115 17 E4051-E60 10.1073/pnas.1801340115 29632189 PMC5924929 · DOI
  176. [189]Ye L Park JJ Peng L Yang Q Chow RD Dong MB A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy Cell Metab. 2022 34 4 595 614.e14 10.1016/j.cmet.2022.02.009 35276062 PMC8986623 · DOI
  177. [190]Wang D Prager BC Gimple RC Aguilar B Alizadeh D Tang H CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies Cancer Discov 2021 11 5 1192 211 10.1158/2159-8290.CD-20-1243 33328215 PMC8406797 · DOI
  178. [191]Gurusamy D Henning AN Yamamoto TN Yu Z Zacharakis N Krishna S Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies Cancer Cell. 2020 37 6 818 833.e9 10.1016/j.ccell.2020.05.004 32516591 PMC10323690 · DOI
  179. [193]Legut M Gajic Z Guarino M Daniloski Z Rahman JA Xue X A genome-scale screen for synthetic drivers of T cell proliferation Nature 2022 603 7902 728 35 10.1038/s41586-022-04494-7 35296855 PMC9908437 · DOI
  180. [194]Carnevale J Shifrut E Kale N Nyberg WA Blaeschke F Chen YY RASA2 ablation in T cells boosts antigen sensitivity and long-term function Nature 2022 609 7925 174 82 10.1038/s41586-022-05126-w 36002574 PMC9433322 · DOI
  181. [195]Ren J Zhao Y Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9 Protein Cell 2017 8 9 634 43 10.1007/s13238-017-0410-x 28434148 PMC5563282 · DOI
  182. [196]Klebanoff CA Khong HT Antony PA Palmer DC Restifo NP Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy Trends Immunol 2005 26 2 111 7 10.1016/j.it.2004.12.003 15668127 PMC1388277 · DOI
  183. [197]Neelapu SS Locke FL Bartlett NL Lekakis LJ Miklos DB Jacobson CA Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma N Engl J Med 2017 377 26 2531 44 10.1056/NEJMoa1707447 29226797 PMC5882485 · DOI · Paper page
  184. [198]Jacobson CA Chavez JC Sehgal AR William BM Munoz J Salles G Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial Lancet Oncol. 2022 23 1 91 103 10.1016/S1470-2045(21)00591-X 34895487 · DOI
  185. [199]Heitzeneder S Bosse KR Zhu Z Zhelev D Majzner RG Radosevich MT GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity Cancer Cell. 2022 40 1 53 69.e9 10.1016/j.ccell.2021.12.005 34971569 PMC9092726 · DOI
  186. [200]An F Wang H Liu Z Wu F Zhang J Tao Q Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia Nat Commun 2020 11 1 5928 10.1038/s41467-020-19774-x 33230103 PMC7683530 · DOI
  187. [201]Ghassemi S Durgin JS Nunez-Cruz S Patel J Leferovich J Pinzone M Rapid manufacturing of non-activated potent CAR T cells Nat Biomed Eng 2022 6 2 118 28 10.1038/s41551-021-00842-6 35190680 PMC8860360 · DOI
  188. [202]Agarwalla P Ogunnaike EA Ahn S Froehlich KA Jansson A Ligler FS Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells Nat Biotechnol 2022 40 8 1250 8 10.1038/s41587-022-01245-x 35332339 PMC9376243 · DOI
  189. [203]Cheung AS Zhang DKY Koshy ST Mooney DJ Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells Nat Biotechnol 2018 36 2 160 9 10.1038/nbt.4047 29334370 PMC5801009 · DOI
  190. [204]Zhang C He J Liu L Wang J Wang S Liu L Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia Blood Cancer J 2022 12 6 96 10.1038/s41408-022-00688-4 35750687 PMC9232607 · DOI
  191. [205]Rossig C Pule M Altvater B Saiagh S Wright G Ghorashian S Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia Leukemia 2017 31 5 1087 95 10.1038/leu.2017.39 28126984 · DOI
  192. [206]Park AK Fong Y Kim S-I Yang J Murad JP Lu J Effective combination immunotherapy using oncolytic viruses to deliver CAR targets to solid tumors Sci Transl Med. 2020 12 559 eaaz1863 10.1126/scitranslmed.aaz1863 32878978 PMC9126033 · DOI
  193. [207]Reinhard K Rengstl B Oehm P Michel K Billmeier A Hayduk N An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors Science 2020 367 6476 446 53 10.1126/science.aay5967 31896660 · DOI · Paper page

Cited by

Sorted by citations

Authors
Liu, Y., An, L., Huang, R., Xiong, J., Yang, H., Wang, X., & Zhang, X.
Affiliations
Army Medical University (CN)
Corresponding author
  • Wang, Xiaoqi
  • Zhang, Xi
ORCID
Venue
Biomarker Research
Publisher
Springer Science and Business Media LLC
Published
2022-11-23
Volume
10
Issue
1
Pages
86-86
ISSN
2050-7771 (ISSN-L)
DOI
10.1186/s40364-022-00434-9
PMC
PMC9685914
OpenAlex
W4309884196
Cited by
97
References
14
Citations by year
2026: 21 · 2025: 29 · 2024: 33 · 2023: 14
FWCI
2.32
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomarker Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Natural Science Foundation of Chongqing, China (No. CSTB2022NSCQ-MSX1287)
  • National Natural Science Foundation of China (No. 82020108004)
  • Special Funding for the Frontiers of Military Medical Basics (No. 2018YQYLY002)
  • Key Technical Innovation Projects in Clinical Fields of Xinqiao Hospital (No. 2018JSLC0020)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CAR T cell persistence, chimeric antigen receptor T cells, B-cell acute lymphoblastic leukemia, B-cell lymphoma, early recurrence, in vitro culture optimization, cell source selection, hematologic malignancies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review